<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525642</url>
  </required_header>
  <id_info>
    <org_study_id>TAX-619</org_study_id>
    <nct_id>NCT00525642</nct_id>
  </id_info>
  <brief_title>Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer</brief_title>
  <official_title>A Chinese Multi-Center,Randomized Study of Combination or Sequential Use of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy for Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or
      reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node
      positive breast cancer. Also in this group of patients, data from BCIRG-001 trial had shown
      that six cycles of adjuvant TAC (docetaxel, doxorubicin and cyclophosphamide) is superior to
      standard FAC (5-FU, doxorubicin and cyclophosphamide ) combination in terms of both disease
      free and overall survival, while associated with a higher rate of febrile neutropenia. Then
      question arose whether it is better to use docetaxel and anthracycline in combination or
      sequence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this national wide study, women with node positive operable breast cancer are eligible for
      inclusion.Patients were designed to randomize to six cycles of adjuvant TAC (Taxotere®
      75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2), and four
      cycles of T(100mg/m2), followed by 4 cycles of AC(doxorubicin 60mg/m2 or epirubicin 75mg/m2
      ,cyclophosphamide 600mg/m2). Prophylaxis with G-CSF was allowed for two arms when febrile
      neutropenia occurred in the first cycle of the study treatment. The second endpoint of this
      study is disease free survival. The primary objective is to compare the disease free survival
      rate and safety profiles of the above mentioned two arms.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2003</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years and 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade III/IV Adverse Event,Severe Adverse Event</measure>
    <time_frame>during chemotherapy and 30 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years and 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease free Survival</measure>
    <time_frame>5 years and 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>5 years and 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Adjuvant</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>six cycles of adjuvant TAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>four cycles of T followed by 4 cycles of AC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide</intervention_name>
    <description>Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Docetaxel=Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide</intervention_name>
    <description>Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Docetaxel= Taxotere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pT1-3,pN1-3,M0, operable breast cancer

          -  Karnofsky &gt;=80

          -  Pregnant test negative

        Exclusion Criteria:

          -  Prior Chemotherapy with anthracyclines and / or Taxanes, except for Neoadjuvant
             therapy

          -  Prior breast radiation

          -  Bilateral breast cancer

          -  in-operable breast cancer

          -  Other health condition which may be contraindications for chemotherapy

          -  contraindications for Dexamethasone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenzhou Shen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Hospital / Institute, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiming Shao, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Hospital / Institute, Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing 307 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No2 affiliated hospital of Sun Yat-sen medical Univesity</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Province Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital / Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai No.6 hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.</citation>
    <PMID>15761078</PMID>
  </reference>
  <reference>
    <citation>Yang L, Li LD, Chen YD, Parkin DM. [Time trends, estimates and projects for breast cancer incidence and mortality in China]. Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):438-40. Chinese.</citation>
    <PMID>17152490</PMID>
  </reference>
  <reference>
    <citation>Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.</citation>
    <PMID>15930421</PMID>
  </reference>
  <reference>
    <citation>Nabholtz JM, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc. Amer. Soc. Clin. Oncol. (1999) 18: 127a (Abstr 485).</citation>
  </reference>
  <reference>
    <citation>I.B.Ambulkaar, et al.Neoadjuvant sequential chemotherapy with docetaxel followed by epirubicin and cyclophosphamide in locally advanced breast cancer. Proc. Amer. Soc. Clin. Oncol. 2003 (Abstr 226)</citation>
  </reference>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <last_update_submitted>September 4, 2007</last_update_submitted>
  <last_update_submitted_qc>September 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2007</last_update_posted>
  <keyword>Breast-adjuvant</keyword>
  <keyword>Breast-chemotherapy</keyword>
  <keyword>Combination chemotherapy regimens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

